Background Deep brain stimulation (DBS) has been proposed as a treatment option for severe Tourette syndrome (TS), based on open-label series and blinded data from a small number of individuals. This study aimed to further evaluate the safety and efficacy of bilateral globus pallidus internus (GPi) DBS in this patient group.
Summary
Background Deep brain stimulation (DBS) has been proposed as a treatment option for severe Tourette syndrome (TS), based on open-label series and blinded data from a small number of individuals. This study aimed to further evaluate the safety and efficacy of bilateral globus pallidus internus (GPi) DBS in this patient group.
Methods
In this randomized, double-blind, crossover trial, eligible patients (severe medically refractory TS, aged ≥20 years old) were recruited from 2 tertiary movement disorders clinics in the UK, received GPi DBS surgery, then were randomly assigned (1:1) to either "stimulation-ON first" or "stimulation-OFF first" for a three-month period followed by a switch to the opposite condition for a further three-month period. Neither patients nor rating clinicians were aware of their computer-generated treatment allocation. An unmasked clinician was responsible for programing the stimulation. The primary endpoint was the difference in Yale Global Tic Severity Scale (YGTSS) total score between the two blinded conditions using repeated measures ANOVA. After completing the double-blind crossover period, patients continued to have open-label stimulation adjustments and objective assessments of tic severity until database lock one month after the final patient's final trial related visit. The trial was registered with ClinicalTrials.gov, number NCT01647269.
Introduction
The clinical hallmark of Tourette syndrome (TS) is the presence of multiple motor and vocal tics, often preceded by premonitory sensations or urges and frequently complicated by neurobehavioral comorbidities, including attention deficit hyperactivity disorder (ADHD), obsessive compulsive disorder (OCD), impulse control disorder, self-injurious behaviour (SIB), as well as personality and mood disorders. [1] [2] [3] The majority of TS patients experience a pre-pubertal increase in tic severity, followed by a remission towards late adolescence or early adulthood. Nevertheless, a significant number of patients may continue to experience disabling symptoms in adulthood and require lifelong treatment. 4 Behavioural therapies, alpha-2 adrenergic agonists, antipsychotic agents, anticonvulsant drugs, benzodiazepines, and botulinum toxin injections may all offer some symptomatic relief. 2, 3 Nevertheless in a proportion of patients, these approaches are insufficiently effective or accompanied by intolerable side effects and among this group there remain a number of severely affected patients for whom surgical approaches such as deep brain stimulation (DBS), may present an alternative treatment option. 5 The first report of DBS for the treatment of refractory TS was published in 1999 by Vandewalle et al, targeting the same thalamic nuclei, (i.e. centromedian /parafascicular complex -CM/Pf, and ventral oral internus nuclei) which were subject to stereotactic ablation by Hassler & Dieckmann in the 1970s. 6, 7 Since then, various areas of the brain have been targeted by DBS including the centromedian-parafascicular complex of the thalamus, the subthalamic nucleus, nucleus accumbens and anterior limb of the internal capsule, and the globus pallidus internus and externus, providing variable but generally positive results. 5 Supportive evidence is however mostly based on case reports or in small case series typically in non-blinded studies involving limited number of patients. Open-label beneficial effects of DBS targeting the CM/Pf thalamic nuclei have been partially supported by two small randomized trials including 5 and 6 patients respectively, but have raised significant issues about the safety and tolerability of this target. [8] [9] [10] There is extensive evidence for the efficacy of GPi DBS in other hyperkinetic movement disorders, L-dopa induced dyskinesia, or various forms of dystonia that support the use of GPi as an attractive alternative target for DBS in TS. 11, 12 In a series of 3 patients comparing bilateral thalamic and bilateral anteromedial GPi stimulation, combined and sham stimulation, Welter and co-workers demonstrated an advantage of anteromedial GPi DBS that was sustained for 20-60 months of follow-up. 13 Further open-label studies have also suggested that GPi DBS might be a promising therapeutic alternative for severe medically refractory TS with an acceptable safety profile. [14] [15] [16] However, there remain a number of unanswered questions regarding DBS for TS including; the objective demonstration of its efficacy on different aspects of TS, the factors that predict individual patient responsiveness, as well as the methods for deriving optimal stimulation parameters, and the precise optimal choice of brain target. Thus, DBS for TS is still considered as an experimental approach. Well-designed randomized double-blind trials, involving a multi-disciplinary team approach are needed to help address these questions. In the current trial, we assessed the clinical efficacy and safety of bilateral GPi DBS in a cohort of 15 patients with treatment refractory, severe TS, using a randomized, double-blind, crossover design followed by ongoing open-label evaluation.
Methods

Patients
Patients were eligible for inclusion if they were adults with stable Tourette's syndrome; had chronic and severe tic disorder with severe functional impairment in Yale Global Tic Severity Scale (YGTSS) of at least 35/55 for at least 12 months prior to surgery; had failed conventional medical treatment at therapeutic doses of three classes of medication; behavioural intervention had been considered inappropriate or had been unsuccessful; had optimised treatment of co-morbid conditions for at least 6 months; and were compliant with any psychosocial interventions/ with surgical treatment plans. The exclusion criteria were: tic disorder attributable to another condition; presence of other medical or psychiatric disorders that might increase the risk of the procedure; psychosocial factors which might impede operative/post-operative care and research participation; coagulation problems; other disease compromising life expectancy; still likely to benefit from psychological intervention; pregnancy; age < 20 years.
Study design
The study was sponsored by University College London, and was conducted in two academic centres in the UK (UCL Institute of Neurology, London and Salford Royal NHS Foundation Trust, Manchester). The study was designed to compare tic severity during 3 months "ON-stimulation" with 3 months "OFF-stimulation" in a randomized double-blind, sham stimulation controlled, crossover manner. The trial conformed to the Declaration of Helsinki, Good Clinical Practice guidelines, and was approved by the ethics committees at participating centres. All patients provided written informed consent before enrolment. The trial was registered with ClinicalTrials.gov, number NCT01647269.
Procedures
Each patient was screened for eligibility at a multidisciplinary evaluation, including assessment by at least one neurologist, functional neurosurgeon, neuropsychiatrist and neuropsychologist (figure 1). All patients underwent a baseline assessment, followed four weeks later by stereotactic implantation of bilateral DBS electrodes (model 3387 or 3389, Medtronic, Minneapolis, MN, USA) into the GPi. In London, implantation of bilateral DBS electrodes was guided by individual targeting on stereotactic proton density MRI, visualizing the individual pallidal target. A Leksell stereotactic frame was used, without microelectrode recording and with immediate postoperative stereotactic MRI to document electrode location in relation to the patient's individual anatomy. All patients were operated under general anaesthesia. Full details of this neurosurgical procedure have been published previously. 17, 18 In Salford, target verification was confirmed using MR imaging of bilateral plastic stylettes prior to the insertion of the final DBS electrodes that followed the same trajectory. 19 All patients received Activa ® PC, (Medtronic, Minneapolis, MN, USA) implantable pulse generators (IPGs).
All participants were scheduled for a first post-operative assessment six weeks following DBS implantation. Following this assessment, patients were screened for the effects of stimulation. Stimulation parameters were adjusted during a one-week un-blinded period. The optimal settings were determined by using the most effective parameters on tics with the lowest energy, without causing side effects. Patients were then randomly assigned in pairs to "stimulation-ON first" or "stimulation-OFF first", for the subsequent three months, following which they would switch to the opposite condition. The patients were routinely contacted at least once monthly and intermediate blinded adjustments/ pseudo-adjustments were performed by a non-blinded member of the trial team, as instructed by the blinded clinician according to tic control/reported side effects. Detailed assessments were scheduled at the end of each of the three-month blinded periods (figure 1).
At the end of the blinded trial period patients were given the option of having their stimulators permanently switched ON. Patients were invited to routine follow-up and assessed in an open-label fashion at least every 6 months until database lock, with further adjustments to their stimulation parameters made as necessary. Randomization and masking Participants were randomly assigned to either "stimulation-OFF first" during which they received no stimulation, or "stimulation-ON first". Computer-generated pairwise randomization was performed according to order of enrolment so that comparable numbers of patients were recruited to receive each condition first. The randomization sequence was generated by the chief investigator and only revealed to the unblinded clinician responsible for the programming of the stimulation. The patients and the clinicians directly involved in the scoring were not aware of the condition of stimulation. The unblinded clinician responsible for the DBS programming spent the same time adjusting the stimulator of the patients at the start of the ON or OFF-stimulation periods. Adjustment/ pseudo-adjustments were performed in an identical manner during both blinded phases based on instruction from the blinded clinician that response to treatment was sub-optimal and using increments of 0·1-0·2V. The electrical parameters were selected to avoid side effects and amplitudes gradually increased at the start of the ON period to avoid any sensation of stimulation being perceived by the patients.
Outcome measures The pre-specified primary end point was the difference in tics between the two blinded stimulation conditions including all individuals that completed both blinded phases, as assessed using the YGTSS total score. Pre-specified secondary outcomes were change in the following validated scales: Y-BOCS, GTS-QOL, BDI, NPI, STAI and the battery of neuropsychological tests in OFF-versus ON-stimulation conditions. Additional post-hoc analyses were performed to evaluate the impact of surgery on tic severity prior to stimulation; to compare changes in MRVRS, MOVES scale, motor and vocal tic and impairment subscores of the YGTSS and to assess the change between baseline and openlabel assessments among all patients utilising the latest available open-label follow-up.
Statistical Analysis
The sample size of this study was based on practical considerations, given that available data with regards to efficacy/variance of pallidal DBS for Tourette's syndrome were insufficient to enable a formal power calculation. Raw scores for the primary endpoint for each recruited patient are presented to maximise transparency of the range of outcomes. The primary and secondary endpoints were compared at baseline, OFF-and ON-stimulation using repeated measures ANOVA. Pairwise comparisons (with Bonferroni correction) were performed for those endpoints with significant main effects of timepoint. The effect of randomisation sequence on the difference between blinded ON and OFF YGTSS scores was compared using an unpaired t test. Post hoc comparisons of baseline against open label scores were performed using paired t tests. All data were analysed using Statistical Package for the Social Sciences version 21·0 software (SPSS, Chicago, IL, USA).
Funding
This was an investigator-initiated study with no commercial sponsorship or funding. Funding for DBS procedures was sought from each individual's National Health Service (NHS) primary care trust using individual funding requests in advance of the surgery. The NHS had no role in the design, data collection, analysis or interpretation of the trial or the writing of the report. All authors had full access to all of the data. Dr Foltynie had responsibility for the final decision to submit the report for publication.
Results
Study population
Of 18 patients assessed for eligibility, 15 patients (11 male, mean age 34·7) were enrolled (figure 2). Table 1 summarizes their clinical characteristics.
DBS Surgery
All DBS procedures were performed between August 2011 and April 2014. Thirteen patients had bilateral electrodes in the anteromedial GPi. Two patients with concurrent dystonia/dystonic tics had bilateral electrodes placed slightly more posteriorly towards the posteroventral GPi aiming to maximise improvement in their dystonia while still adhering to the trial protocol, and given the absence of evidence regarding which subregion of the GPi may be most effective for tic suppression (figure 3).
Protocol withdrawals/deviations Two patients withdrew from the ON/OFF blinded crossover phase of the trial, one before and one soon after randomization, because of their concerns of the additional delay in potential therapeutic effects associated with the crossover period. In accordance with their ethics committee approved trial consent, both immediately received open-label continuous stimulation. Thirteen patients completed the randomization period; 6 randomly assigned to "stimulation-ON first" and 7 to "stimulation-OFF first" (figure 2). Three of these had protocol deviations, including 1 patient withdrawing from the blinded phase of the trial 1 month early due to increased anxiety associated with the blinding, and 2 patients having incomplete assessments at trial visits due to patient fatigue. Two patients had medication changes during the 6 months of the blinded protocol (1 patient had initiation of diazepam 5mg and fluoxetine 20mg halfway during stimulation-ON period and continued during stimulation-OFF period due to exacerbation of anxiety, and a second patient discontinued haloperidol during stimulation-OFF period due to intolerance of pre-existing sedative side effects). Table 2 presents the individual and mean YGTSS total scores for all 15 patients. Repeated measures ANOVA revealed a significant interaction between timepoint and YGTSS total scores (Wilks Lamba =0·45, F(2,11)= 6·6, p=0·013). Pairwise comparisons of YGTSS total scores after Bonferroni correction confirmed significantly lower scores at the end of stimulation-ON blinded period in comparison to the end of the stimulation-OFF blinded period (n=13) with a mean improvement of 12·4 points (95% CI 0·1-24·7, p=0·048), equivalent to 15·3%.
Efficacy of stimulation -Primary outcome YGTSS
Additional pair-wise comparisons between baseline and OFF stimulation showed an improvement of 7·2 points (95% CI -0·2 -14·7) of marginal significance (p=0·059 after Bonferroni correction), while between baseline and ON stimulation confirmed an improvement of 19·6 points (95% CI 5·0-34·3, p=0·009 after Bonferroni correction). There was no between group difference in the primary outcome according to the sequence of the randomization (t= 0.023, p=0.98).
Efficacy of stimulation-Pre-specified Secondary Outcomes There was a significant effect of timepoint on GTS-QOL and CVLT immediate recall scores (Table 3 ) but no significant differences comparing blinded ON vs OFF stimulation scores after Bonferroni correction (GTS-QOL (p=1.0), CVLT immediate recall (p=0.07)). There were no other significant changes in other secondary outcomes comparing baseline, blinded ON and OFF stimulation timepoints.
Post hoc analyses Seven patients had an improvement in tic severity based on the 6 week post-operative, prestimulation assessment possibly indicating a residual microlesion effect of the surgery ( Table  2 .) In the blinded period comparison of the sub-items of the YGTSS, there was a significant effect of timepoint for the mean motor tic, vocal tic and impairment sub-scores, but only the motor subscore remained significant in the ON compared to the OFF condition after Bonferroni correction (p=0.039). There was also a significant effect of timepoint in the mean MRVRS observed and unobserved scores, together with a significant improvement in the ON compared to OFF condition in the mean observed MRVRS score (p=0.031) (table 3) . Beyond the blinded crossover trial period, all 13 patients opted to have their stimulators permanently switched-ON and (alongside the 2 patients who withdrew from the blinded phase of the trial) were followed on an open-label basis for a mean of 16·7 months (range 8-36) post-operatively. Open-label YGTSS total scores (n=15) at latest follow up were reduced by 40·1% compared with baseline (mean score 51·5 vs 87·9, p<0·0001) (table 2). At this timepoint, all secondary outcome measures were also significantly improved except Y-BOCS and STAI (table 3) .
Optimising stimulation parameters During the blinded period, electrical stimulation was delivered as single monopolar stimulation in 9 patients and as double monopolar stimulation in the remaining 4. The stimulation amplitudes were deliberately constrained to avoid unblinding ON/ OFF status during this period. During the subsequent open-label period, stimulation was further adjusted to achieve maximal symptom control, including further titrations of voltage, pulse-width and frequency, the addition of contacts in 3 patients, and complete change of active contacts in 4 patients. For DBS parameters-See Supplementary material. Adverse events Surgery was well tolerated and all patients were ambulatory within 24h. Adverse events were recorded until database lock (mean period of 16·7 months (range 8-36). Three serious adverse events (20%) were reported of which 2 were surgery related and 1 was stimulation related. Patients 3 and 7 developed infection of the DBS hardware which necessitated the removal of leads, extension cables and IPG and administration of antibiotics. Both patients opted to re-enter the trial and were re-implanted 22 months and 6 months post initial operation and completed the trial protocol as above. One patient experienced deterioration of tics and hypomanic behaviour during the ON-stimulation condition. Hospital admission was necessary, following re-screening and alteration of stimulation settings accompanied by addition of medications. Over the whole study period, including the open-label extension of the study, an additional 23 adverse events occurred in 10 patients, 15 of which resolved (table 4) .
Discussion
In this double-blind, crossover trial of 15 patients with severe medically refractory TS, globus pallidus stimulation led to a significant improvement in tics during the ON compared to the OFF blinded condition, with an overall acceptable safety profile. There was a wide range of improvements observed during the rigorous double-blind evaluation with greater consistency following the initiation of open-label stimulation adjustment. To our knowledge, this is the largest double-blind trial of DBS in TS patients published to date, although we are aware that other teams are also evaluating this potential target in this population.
The modest improvement we observed in the mean YGTSS and video-based tic counts during the blinded phase of the trial, was not reflected in a significant improvement in mean quality of life (GTS-QOL) scores or any of the co-morbid psychiatric conditions assessed. However, long-term open-label assessment of the patients revealed further mean improvement in tics (40·1%) compared with pre-operative baseline, and at latest follow-up, continuous GPi stimulation led to a significant mean improvement (38·9%) in quality of life. Mood, assessed by BDI also significantly improved, whereas only modest, non-significant effects were seen in obsessive compulsive behaviours (Y-BOCS), and anxiety (STAI). Greater improvements were seen in motor compared with vocal tics in blinded evaluations, although efficacy was similar for tic subtypes in the open-label analysis.
The individual patient responses were presented to maximise transparency; in 6 patients there was no clear benefit from stimulation during the blinded phase of the trial (< 10% improvement in YGTSS). In the majority of these individuals, a clear improvement was obvious in open-label assessment following further changes of the stimulation parameters which was consistently contact-specific and reproducible. This is an issue for DBS related trials, where adjusting the stimulation while maintaining treatment blinding can compromise the identification/use of optimal settings therefore suboptimal stimulation parameters may be used out of necessity. In addition, anxiety associated with uncertainty whether stimulation was switched ON or OFF, was a particular issue in some patients, which could also at least partly explain the more limited effect in patients' quality life during the blinded period. The additional contribution of a transient/persisting post-operative microlesion effect impacting on subsequent ON verses OFF stimulation YGTSS assessments in certain patients, cannot be excluded.
During open-label optimisation of the stimulation, there were clear improvements in quality of life considering the group as a whole. Nevertheless, four patients had less than 20% improvement in YGTSS scores compared with baseline without obvious explanation. A complex interplay between severity and chronicity of tics on an individual's learned behaviour, comorbid psychiatric symptoms, stimulation related side effects, and also patients' expectations may explain the variability of response to stimulation in these patients.
Most patients responded to average stimulation parameters comparable to those used in Parkinson's disease, with higher levels of stimulation sometimes having a negative impact. However, in several patients, and in those showing good response patterns in particular, progressive increases in amplitude of stimulation and number of active contacts was necessary over time. This raises a concern that tolerance to stimulation may occur and also of accelerated battery depletion, both important issues for the long-term care of this relatively young population of patients. Of note is that the most dorsal contacts on the electrodes were frequently associated with optimal tic responses possibly indicating that stimulation of the globus pallidus externus (GPe) might be involved in the mechanism of tic relief. 20 To date, the thalamic DBS target probably remains the best explored in TS. [8] [9] [10] [21] [22] [23] [24] However, despite impressive benefits seen in open-label studies, results have also been more modest in small double-blind trials of thalamic DBS for TS. The potential role of thalamic DBS for TS with respect to both efficacy and side effects remains a source of debate with some centres continuing to report positive open label results 24 .
In our trial, GPi stimulation was generally well tolerated and stimulation related side effects were amenable to stimulation adjustment. Of concern is the infection rate (13%) which is higher than expected, and may reflect that higher infection rates are indeed associated with DBS in this population, previously estimated to be as high as 18%. 25, 26 Whether this is due to patients' behaviour or distinct immunological profiles in this population remains unclear.
A limitation of our study remains the relatively small sample size and that in 2 individuals electrodes were placed more posteriorly in the GPi as directed by their concurrent dystonic features. We cannot conclude whether anteromedial GPi DBS is superior to posteroventral GPi DBS for tic suppression based on our results. Moreover, in 2 patients medication changes occurred during the blinded period (1 increased, 1 decreased) and thus any influence of these changes aside from DBS cannot be excluded. Due to the immediate and often obvious effects of DBS adjustment, both blinding and subsequent adherence to trial protocol can be easily compromised unless adjustments are limited to minor potentially subtherapeutic changes. Even so, delivery of effective stimulation in severely affected patients can make maintenance of double-blinding difficult. These challenges may be overcome in future trials by randomising patients to different targets, or comparing different targets within patients. However, the common coexistence of significant psychiatric comorbidity, the subjective nature of TS related outcome measures and their potential ceiling effects in the most severely affected patients, add to the difficulties of trial conduct in TS patients and interpreting the results based on individual scales.
In conclusion, our data support the GPi as an attractive alternative for DBS in TS. The mean effect size observed in the blinded period is greater than that seen in double-blind trials of medications for TS, and with further follow-up, GPi DBS appears to have major effects on tic severity and quality of life of this extremely disabled patient group. The anteromedial GPi is considered as part of the same limbic pathways that are thought to be involved in tic generation, [27] [28] [29] [30] and while it is likely that tics emerge from network based neuronal dysfunction, bilateral DBS surgery appears to be well tolerated when targeting the pallidum. Additionally the pallidal target can be easily visualized on pre-operative stereotactic MRI allowing uniformity of targeting across patients. Future trials comparing the optimal target for DBS for TS should include a comparator arm with electrodes in bilateral anteromedial GPi/ GPe, and continue to try and identify those factors, which predict individual patient responsiveness.
Panel: Research in context
Evidence before this study We searched PubMed up to December 2014 with the terms Tourette's syndrome, Gilles de la Tourette, or Tourette and deep brain stimulation, or DBS for double-blind randomized trials. We identified 4 small trials incorporating double-blind randomized methodology. In two trials including 5 and 6 patients respectively, the efficacy of thalamic DBS (centromedianparafascicular (CM-Pfc) and ventralis oralis complex of the thalamus) was evaluated. 9, 10 In another two trials, the effect of thalamic and anteromedial GPi stimulation was compared in 1 and 3 patients respectively. 13, 31 These studies, including very small numbers of patients each report a benefit from stimulation, and thus partially support the overall positive outcomes presented in open-label studies. However, the literature of DBS for the treatment of Tourette syndrome consistently highlights the paucity of the highest level of evidence for its use. There remains a need for double-blind, randomized, controlled trials, with a sufficient number of patients to address a number of unresolved issues including; the magnitude and consistency of the efficacy of this treatment, its clinical relevance, its effect on comorbid conditions, and the overall safety of this approach. The brain target as well as stimulation settings that can optimally address the abovementioned issues also remain to be determined.
Added value of this study Our prospective, randomized trial is the largest double-blind trial of DBS in TS patients to date, assessing the safety and efficacy of pallidal DBS. Our results provide high-quality evidence that GPi DBS can significantly improve tics and can have major effects in quality of life in the long-term, while having an acceptable safety profile.
Implications of all the available evidence The outcomes of this study provide further justification for the use of GPi DBS as a treatment for patients with severe medically refractory TS, which to date was supported by limited evidence. Future trials will likely require cross-centre collaboration to recruit larger numbers and evaluate the relative merits of different DBS targets, and identify factors predictive of useful response to surgery.
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